Last call on FierceBiotech's deal-making survey

We're wrapping up the final preparations for tomorrow's big webinar on landing the best deal for your biotech company, and I want to give readers one last opportunity to take FierceBiotech's short survey on deal-making plans. Over the last year we've seen pharma companies turning increasingly to new alliances as a low-cost, low-risk approach to drug development. And the trend has had a profound impact on the biotech industry. Let us know more about where you stand in the process here. It will only take about a minute. - John Carroll

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.